Adaptive Biotechnologies (ADPT) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Adaptive Biotechnologies Corporation  (NASDAQ: ADPT)


Adaptive Biotechnologies's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Adaptive Biotechnologies's ROA in the second quarter of 2026?
Adaptive Biotechnologies Corporation recorded a cumulative net loss of $-64 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -11.84%.

However, within the Healthcare sector 311 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3184, from total ROA ranking in the first quarter of 2026 at 3822.

What is ROA?



Return On Assets (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 29.02 % -0.84 % -2.67 % -12.38 % -15 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -64 -50 -59 -80 -121
Return On Assets (TTM) -11.84 % -9.84 % -11.76 % -15.63 % -23.02 %
ADPT's Total Ranking # 3184 # 3822 # 3447 # 3644 # 3764
Total Assets (TTM) in million 641 506 526 490 497
Seq. Total Assets Change 26.63 % -3.81 % 7.32 % -1.3 % -2.68 %
Seq. Net Income Change - - - - -



Return On Assets Company Ranking
Within: No.
Industry # 31
Sector # 312
Overall # 3238

Return On Assets Statistics
High Average Low
27.01 %
-12.23 %
-33.06 %
(Jun 30 2016)   (Jun 30 2024)





Financial Statements
Adaptive Biotechnologies's Assets $ 641 million ADPT's Balance sheet
Adaptive Biotechnologies's Income $ -40 million Quarterly ADPT's Income Statement
ADPT's Income by Division See ADPT's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025
(Dec 31 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
Y / Y Total Assets Change -2.67 % -18.18 % -22.87 % -7.25 % -17.29 %
Total Assets in million 526 540 661 856 923
Y / Y Net Income Change - - - - -
Net Income in million -59 -160 -225 -200 -207
Annual Return On Assets -11.3 % -29.53 % -34.11 % -23.4 % -22.45 %




More Return On Assets Ratios
ADPT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADPT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADPT's Competitors
Subscribers only: Roa for Adaptive Biotechnologies's Suppliers
Subscribers only: Return On Assets for ADPT's Customers

You may also want to know
ADPT's Roi ADPT's Inventory Turnover Ratio ADPT's Growth Rates ADPT's Dividend Comparisons
ADPT's Profitability Ratios ADPT's Asset Turnover Ratio ADPT's Dividend Growth
ADPT's Roe ADPT's Valuation Ratios ADPT's Financial Strength Ratios ADPT's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA


Date modified: 2026-09-12T06:23:50+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.